Oncology
Denosumab▼ Biosimilar UK SmPC can be found here. Adverse Events Reporting can be found at the bottom of this infographic.
The publication of this infographic was supported by SANDOZ.
Myelofibrosis is a rare and progressive myeloproliferative neoplasm associated with bone marrow fibrosis, systemic symptoms, splenomegaly, and anaemia. During interviews conducted by EMJ, three leading haematologists, Claire Harrison from Guy’s and St Thomas’ NHS Foundation Trust in London, UK; Francesca Palandri from the University of Bologna in Italy; and Prithviraj Bose from the University of Texas MD Anderson Cancer Center in Houston, USA, explored the latest advancements in myelofibrosis treatment. Experts discussed updated clinical and real-world evidence for Janus kinase inhibitors (JAKi) in myelofibrosis and explored new data on innovative treatment approaches in the pipeline, focusing on key presentations from the American Society of Hematology (ASH) and European Hematology Association (EHA) annual congresses in 2025.
Interview Summary
Funding Statement: The publication of this article was funded by GSK. Disclosure: Harrison has received research funding from GSK, Incyte, and Novartis; and been an advisor for BMS, Calitryx, Novartis, Galacteo, Geron, Gilead, GSK, Incyte, Ionis, Janssen, Kartos, Karyopharm, Merck, Menarini Stemline, Keros, Takeda, Silence, Sumitomo, Syntara, and SOBI.Palandri has received honoraria and/or been an advisor or consultant for Amgen, AOP, BMS, Grifols, GSK, Incyte, Novartis, Sanofi, Sobi, and Takeda. Bose has received funding from Incyte, BMS, GSK, Novartis, Merck, Ionis, Disc, Sumitomo, Karyopharm, Geron, Janssen, Kartos, Telios, Ajax, Blueprint, and Cogent; and been an advisor or consultant for Incyte, BMS, GSK, Sobi, Novartis, Merck, Takeda, Geron, Ionis, Deciphera, Disc, Sumitomo, Karyopharm, Blueprint, Cogent, AbbVie, Pharma Essentia, Vyne, V6, Damora, Morphic, Jubilant, and Raythera.Disclaimer: The opinions expressed in this article belong solely to the named interviewees. Acknowledgements: Medical writing assistance was provided by Helen Boreham, HB Medical (UK) Ltd, Wetherby, UK, with interactivity curated by Alex Perkins, EMJ, London, UK.
Keywords: American Society of Hematology (ASH), clinical trials, European Hematology Association (EHA), fedratinib, Janus kinase inhibitors (JAKi), momelotinib, myelofibrosis, real-world evidence (RWE), ruxolitinib, SIMPLIFY-1.
Original Citation: EMJ Hematol. 2026;14[Suppl 3]:2-14. https://doi.org/10.33590/emjhematol/XU9G57TG
A 5-YEAR BUDGET IMPACT MODEL FOR BIOSIMILAR DENOSUMAB FOR SREs AND FRACTURES IN THE USA ONCOLOGY POPULATION11
References
Biosimilars in Bone Metastases: First Real-World Data on Switching
In patients with solid tumours, bone is one of the most frequent sites of metastatic spread. Skeletal involvement is associated with substantial morbidity and mortality across cancer types associated with bone metastases.1,2 Bone metastases occur most frequently in prostate cancer, breast cancer, and cancers associated with the head and neck. A large natural language-processing analysis of CT reports found that the 5-year incidence rate of bone metastases was highest in prostate (52%), breast (41%), head and neck (36%), and lung cancer (33%).1
Bone metastases can lead to SREs such as pathological fractures, spinal cord compression, bone pain requiring palliative radiotherapy, orthopaedic surgery.2,3 Severe pain, reduced mobility, loss of independence, and impaired quality of life are commonly seen in patients with bone metastases.2,3
The treatment of bone metastases carries a high global socioeconomic burden for patients, caregivers, and global healthcare systems.1-3
In a 2015 European study, health resource utilisation costs were estimated across different SREs.3
Across countries, mean costs were:3
Denosumab is prescribed to prevent SREs and fractures in patients with bone metastases, but its high cost can remain a barrier to access.10 Biosimilars can provide a lower-cost alternative that may reduce SRE-related costs and broaden treatment access.10
Biosimilars are biological medicines with an identical amino acid sequence along with structural and functional similarity to an already-approved medicine.4 Biosimilars are approved according to the same standards of pharmaceutical product quality as the already-approved medicine.4
BIOSIMILARS CAN IMPROVE ACCESS TO MEDICINES AND REDUCE COST4
Biosimilars can offer advantages to patients and healthcare systems. Having biosimilar alternatives available improves access to treatment and reduces cost, so that more patients can be treated.5-9
Since the early 2000s, Sandoz (Basel, Switzerland) has obtained approval for 13 marketed biosimilars across nearly 100 countries.4,10
Cancer and its related treatments are often associated with significant costs. With the use of biosimilars, healthcare systems can potentially reduce healthcare costs and increase access to therapy.10
Biosimilar denosumab is indicated for the prevention of SREs in adult patients with advanced malignancies involving bone.11
The study aimed to evaluate the budget impact of integrating biosimilar denosumab into a health plan formulary, as well as estimate biosimilar treatment opportunities and evaluate the impact on downstream costs.
Two models were developed to estimate budget impact of biosimilar denosumab for treating oncology indications from a USA payer perspective.
Methods11
Results and Conclusion11
The first model evaluated total cost savings associated with patients currently receiving reference denosumab switching to biosimilar denosumab.
The second model assessed reinvestment potential of savings estimated from the first model, simulating oncology practices expanding biological therapy access via biosimilar conversion.
Cost Savings: Modelling a hypothetical USA health plan with one million covered lives, switching to biosimilar denosumab resulted in a total cost savings of 38,677,606 USD over the 5-year period.
Methods11
Results and Conclusion11
Downstream Benefit: It was estimated that approximately 100 additional patients could be treated with biosimilar denosumab, and an additional three SREs and fractures could be prevented with each 10% increase in reinvestment.
Methods11
Results and Conclusion11
Overall, switching to biosimilar denosumab was estimated to be financially favourable and enables expanded treatment access to patients with cancer.
Methods11
Results and Conclusion11
In Canada, a non-interventional study assessed the satisfaction of patients with bone metastases when switching from reference denosumab to biosimilar denosumab.12
The study included 217 adults.12
PATIENT-REPORTED EXPERIENCE OF SWITCHING FROM REFERENCE TO BIOSIMILAR DENOSUMAB IN ONCOLOGY12
Primary endpoints included overall satisfaction with the switch, as well as the perceived economic importance of switching.12
reported high satisfaction at the time of the switch, and 77% reported high satisfaction 3 months after the switch.
82%
reported receiving information in advance of their switch from reference to biosimilar denosumab.
69%
reported effective HCP communication about the switch.
80%
valued the affordability of biosimilar denosumab.
82%
Adverse events should be reported. Reporting forms and information for the United Kingdom can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to your local Sandoz Patient Safety Responsible person via adverse.event.uk@sandoz.com.
Long N et al. Cancers. 2025;17(2):218.DiCaprio MR et al. Ann Jt. 2022;7:28.Pereira J et al. JME. 2016;19(6):611-8.Sagi S et al. Drug Saf. 2023;46(12):1391-404.European Medicines Agency (EMA). 2023. Available at: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Last accessed: 23 March 2026. IQVIA. 2021. Available at: https://www.iqvia.com/library/white-papers/the-impact-of-biosimilar-competition-in-europe-2021. Last accessed: 2 March 2026.IQVIA. 2023. Available at: https://secure.constellation.iqvia.com/OmintropeReport. Last accessed: 9 December 2025. de Mora F. BioDrugs. 2019;33(4):353-6.International Coalition of Medicines Regulatory Agencies (ICMRA). Available at: https://icmra.info/drupal/sites/default/files/2019-07/ICMRA_statement_about_confidence_in_biosimilar_product_HCP.PDF. Last accessed: 2 March 2026.Sandoz Group AG. Sandoz Integrated Annual Report 2025. Available at: https://www.sandoz.com/investors/annual-report/. Last accessed: 2 March 2026. Flanigan J et al. JME. 2025;28(1):2027-38. Jerzak K et al. Abstract 2528. ESMO Congress, 23-27 October, 2026. SRE: skeletal-related event.SRE: skeletal-related event.
1. 2. 3. 4. 5. 6.
7.
8. 9.10.
11.12.
References & Abbreviations
